Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Inclusion Criteria: * HIV-1 infection * On a suppressive ART regimen for at least 24 months with no changes in the 90 days prior to study entry * CD4+ cell count greater than 200 cells/mm3 obtained within 56 days prior to study entry * HIV-1 RNA \<200 copies/mL obtained within 56 days prior to study entry * Plasma HIV-1 RNA levels \<200 copies/mL for at least 12 months on ART prior to study entry * The following laboratory values obtained within 56 days prior to study entry * White blood cell count ≥2,500 cells/mm3 * Absolute neutrophil count (ANC) \>750/mm3 * Hemoglobin ≥11 g/dL for cisgender men/transgender women and ≥10 g/dL for cisgender women/transgender men * Platelet count ≥100,000/mm3 * Creatinine \<1.5x upper limit of normal (ULN) * Alanine aminotransferase (ALT) (SGPT) ≤1.5 ULN * Hepatitis C Virus (HCV) antibody-negative or HCV RNA negative result if indicated, within 56 days prior to study entry * Negative hepatitis B surface antigen (HBsAg) result obtained within 56 days prior to study entry * For study candidates of child-bearing potential, negative serum or urine pregnancy test at screening and within 48 hours prior to study entry * No participation in conception process and agree to use at least one reliable form of contraception if participating in sexual activity that could lead to pregnancy during the study and for 8 weeks following the final study vaccine Exclusion Criteria: * Known to have started ART during acute HIV infection * Known to h…